The study extensively uses both secondary and primary research methodologies. More than 100 industry experts from different phases of the value chain (supply side, demand side, resellers/distributors, and independent consultants) were interviewed to gain key insights about the market and validate the research findings. Secondary sources referred for the research study include company websites, annual reports, paid database tools, investor presentations, webinars, blogs, news/journals, whitepapers, survey papers, associations, and government websites. All the collected data and insights were then processed using our proprietary data mining software that executes various algorithms to make projections for the forecast period.

 1     Executive Summary

 2     Market Introduction
 2.1     Definition
 2.2     Architecture
 2.3     Evolution
 2.4     Scope of the Study
 2.5     Related Stakeholders

 3     Research Methodology
 3.1     Introduction
 3.2     Primary Research
 3.2.1     Key Insights
 3.2.2     Breakdown of Primary Interviews
 3.3     Secondary Research
 3.3.1     Important Sources
 3.4     Market Size Estimation Approaches
 3.4.1     Top-Down Approach
 3.4.2     Bottom-Up Approach
 3.4.3     Data Triangulation
 3.5     List of Assumptions

 4     Market Dynamics
 4.1     Introduction
 4.2     Drivers
 4.2.1     Growing COVID-19 outbreak, globally
 4.2.2     Increasing Prevalence of Contagious Disease
 4.2.3     Growing Inclination towards Health and Wellness
 4.3     Restraints
 4.4     Opportunities
 4.5     Trends
 4.6     Porter's Five Forces Model Analysis
 4.7     Value Chain Analysis
 4.8     Regulatory Landscape

 5     Global Hydroxychloroquine for COVID-19 Market, By Dosage Type
 5.1     Introduction
 5.2     100mg
 5.3     200mg
 5.4     400mg
 5.5     Others

 6     Global Hydroxychloroquine for COVID-19 Market, By Region
 6.1     Introduction
 6.2     North America
 6.2.1     US
 6.2.2     Canada
 6.2.3     Mexico
 6.3     Europe
 6.3.1     Germany
 6.3.2     UK
 6.3.3     France
 6.3.4     Switzerland
 6.3.5     Ireland
 6.3.6     Rest of Europe
 6.4     Asia-Pacific
 6.4.1     India
 6.4.2     China
 6.4.3     Japan
 6.4.4     Australia
 6.4.5     Rest of Asia-Pacific
 6.5     Rest of the World

 7     Competitive Landscape
 7.1     Introduction
 7.2     Vendor Evaluation Criteria
 7.3     Vendor Share Analysis, 2020 Q2

 8     Company Profiles

 8.1     Sanofi
 8.1.1     Business Overview
 8.1.2     Financial Overview
 8.1.3     Product Offerings
 8.1.4     Recent Developments
 8.1.5     SWOT Analysis
 8.1.6     Key Strategies
 8.2     Hikma Pharmaceuticals
 8.2.1     Business Overview
 8.2.2     Financial Overview
 8.2.3     Product Offerings
 8.2.4     Recent Developments
 8.2.5     SWOT Analysis
 8.2.6     Key Strategies
 8.3     Novartis
 8.3.1     Business Overview
 8.3.2     Financial Overview
 8.3.3     Product Offerings
 8.3.4     Recent Developments
 8.3.5     SWOT Analysis
 8.3.6     Key Strategies
 8.4     Actavis (TEVA )
 8.4.1     Business Overview
 8.4.2     Financial Overview
 8.4.3     Product Offerings
 8.4.4     Recent Developments
 8.4.5     SWOT Analysis
 8.4.6     Key Strategies
 8.5     Apotex Corporation
 8.5.1     Business Overview
 8.5.2     Financial Overview
 8.5.3     Product Offerings
 8.5.4     Recent Developments
 8.5.5     SWOT Analysis
 8.5.6     Key Strategies
 8.6     Mylan
 8.6.1     Business Overview
 8.6.2     Financial Overview
 8.6.3     Product Offerings
 8.6.4     Recent Developments
 8.6.5     SWOT Analysis
 8.6.6     Key Strategies
 8.7     Covis Pharmaceutical
 8.7.1     Business Overview
 8.7.2     Financial Overview
 8.7.3     Product Offerings
 8.7.4     Recent Developments
 8.7.5     SWOT Analysis
 8.7.6     Key Strategies
 8.8     Aphena Pharma
 8.8.1     Business Overview
 8.8.2     Financial Overview
 8.8.3     Product Offerings
 8.8.4     Recent Developments
 8.8.5     SWOT Analysis
 8.8.6     Key Strategies
 8.9     Ipca Laboratories
 8.9.1     Business Overview
 8.9.2     Financial Overview
 8.9.3     Product Offerings
 8.9.4     Recent Developments
 8.9.5     SWOT Analysis
 8.9.6     Key Strategies
 8.10     Cinkate Corporation
 8.10.1     Business Overview
 8.10.2     Financial Overview
 8.10.3     Product Offerings
 8.10.4     Recent Developments
 8.10.5     SWOT Analysis
 8.10.6     Key Strategies
 8.11     Other Companies
 8.11.1     Zydus Cadila
 8.11.2     AvKARE
 8.11.3     Bristol Laboratories
 8.11.4     Cadila Healthcare
 8.11.5     Taj Pharmaceuticals
 8.11.6     Advanz Pharma
 8.11.7     Sun Pharma
 8.11.8     Shanghai Pharmaceuticals Holding
 8.11.9     Hanlim Pharmaceutical
 8.11.10     Kyung Poong
 

9     Appendix
 9.1     Discussion Guide
 9.2     Customization Options